Table III.

Associations between the expression of AXL and the clinical characteristics.

	Expression of AXL, n
Variable	Patients, n	−	+	Positive rate, %	P-valuea
Total	257
Gender					0.238
Male	190	81	109	57.37
Female	67	36	31	46.27
Age					0.722
≤60 years	111	48	63	56.76
>60 years	146	69	77	52.74
Histological type					1.000
Adenocarcinoma	143	66	77	53.85
Squamous cell carcinoma	114	51	63	55.26
Differentiation					0.001
Well	44	33	11	25.00
Moderate	140	71	69	49.29
Poor	73	13	60	82.19
TNM stage					0.005
Stage I	47	35	12	25.53
>Stage I	210	83	127	60.48
Lymph node metastasis					0.091
Yes	115	44	71	61.74
No	142	73	69	48.59
Tumor size					0.166
≤3 cm	92	50	42	45.65
>3 cm	165	67	98	59.39

^aP-values relate to comparison of positive rate between tumor and peritumoral tissue. AXL, tyrosine-protein kinase receptor UFO; TNM, TNM classification of malignant tumors.